Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1

Cancer Immunology Research

Volumn 4, Issue 5, 2016, Pages 383-390

  Naidoo, Jarushka ^a   Schindler, Katja ^b   Querfeld, Christiane ^c   Busam, Klaus ^d   Cunningham, Jane ^d   Page, David B ^e   Postow, Michael A ^d,f   Weinstein, Alyona ^d   Lucas, Anna Skripnik ^d   Ciccolini, Kathryn T ^d   Quigley, Elizabeth A ^d,f   Lesokhin, Alexander M ^d,f   Paik, Paul K ^d,f   Chaft, Jamie E ^d,f   Segal, Neil H ^d,f   D'Angelo, Sandra P ^d,f   Dickson, Mark A ^d,f   Wolchok, Jedd D ^d,f   Lacouture, Mario E ^d,f  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE; CARBOPLATIN; CHECKPOINT KINASE INHIBITOR; CLINDAMYCIN; CLOBETASOL; DURVALUMAB; HYDROXYZINE; IPILIMUMAB; MEPREDNISONE; NICOTINAMIDE; NIVOLUMAB; OFLOXACIN; PACLITAXEL; PREDNISONE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; PSEUDOMONIC ACID; STEROID; TACROLIMUS; TETRACYCLINE; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

AGED; ANTIBIOTIC THERAPY; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BASEMENT MEMBRANE; BLISTER; BULLOUS DERMATITIS; CASE REPORT; DRUG WITHDRAWAL; EOSINOPHIL COUNT; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LICHENOID ERUPTION; MACULOPAPULAR RASH; MALE; METASTATIC MELANOMA; PRURITUS; SKIN BIOPSY; SMALL CELL LUNG CANCER; STEROID THERAPY; T LYMPHOCYTE; TREATMENT DURATION; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; DRUG ERUPTIONS; LUNG NEOPLASMS; MELANOMA; PATHOLOGY; PEMPHIGOID, BULLOUS; SECONDARY; X-RAY COMPUTED TOMOGRAPHY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MELANOMA; PEMPHIGOID, BULLOUS; PROGRAMMED CELL DEATH 1 RECEPTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84976354836     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0123     Document Type: Article

References (25)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Robert C, Thomas L, Bondarenko I, O'Day S, M DJ, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
3. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.
4. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the practitioner. J Clin Oncol 2015;33:2092-9.
5. Minkis K, Garden BC, Wu S, Pulitzer MP, Lacouture ME. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis. J Am Acad Dermatol 2013;69:e121-8.
6. Lacouture ME, Wolchok JD, Yosipovitch G, Kahler KC, Busam KJ, Hauschild A. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol . 2014.
7. Jaber SH, Cowen EW, Haworth LR, Booher SL, Berman DM, Rosenberg SA, et al. Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent. Arch Dermatol 2006;142: 166-72.
8. Voskens CJ, Goldinger SM, Loquai C, Robert C, Kaehler KC, Berking C, et al. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PloS One . 2013;8:e53745.
9. Yervoy [package insert]. Princeton NB-MS. http://www.accessdata.fda.gov/ drugsatfda-docs/label/2011/125377s0000lbl.pdf. 2011.
10. Carlos G, Anforth R, Chou S, Clements A, Fernandez-Penas P. A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab. Melanoma Res 2015;25:265-8.
11. Baum S, Sakka N, Artsi O, Trau H, Barzilai A. Diagnosis and classification of autoimmune blistering diseases. Autoimmun Rev 2014;13:482-9.
12. Sticherling M, Erfurt-Berge C. Autoimmune blistering diseases of the skin. Autoimmun Rev 2012;11:226-30.
13. Kasperkiewicz M, Zillikens D. The pathophysiology of bullous pemphigoid. Clin Rev Allergy Immunol 2007;33:67-77.
14. Schmidt E, Obe K, Brocker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol 2000;136:174-8.
15. Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a review of the literature. J Eur Acad Dermatol Venereol 2014;28:1133-40.
16. Vassileva S.Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol 1998;16:379-87.
17. Krenacs T, Kiszner G, Stelkovics E, Balla P, Teleki I, Nemeth I, et al. Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis. Histochem Cell Biol 2012;138:653-67.
18. Papay J, Krenacs T, Moldvay J, Stelkovics E, Furak J, Molnar B, et al. Immunophenotypic profiling of non-small cell lung cancer progression using the tissue microarray approach. Appl Immunohistochem Mol Morphol 2007;15:19-30.
19. Joly P, Roujeau JC, Benichou J, Picard C, Dreno B, Delaporte E, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med 2002;346:321-7.
20. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Translat Med 2014; 6:230ra45.
21. Liu Z, Sui W, Zhao M, Li Z, Li N, Thresher R, et al. Subepidermal blistering induced by human autoantibodies to BP180 requires innate immune players in a humanized bullous pemphigoid mouse model. J Autoimmun 2008;31:331-8.
22. Bowman C, Delrieu O. Immunogenetics of drug-induced skin blistering disorders. Part I: Perspective. Pharmacogenomics 2009;10: 601-21.
23. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 2002; 99:12293-7.
24. Zitvogel L, Kroemer G. Targeting PD-1/PD-L1 interactions for cancer immunotherapy. Oncoimmunology 2012;1:1223-5.
25. Good-Jacobson KL, Szumilas CG, Chen L, Sharpe AH, Tomayko MM, Shlomchik MJ. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 2010; 11:535-42.